Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR1A | P08908 | 13/20 | 0.69 |
| ▸ | SLC6A4 | P31645 | 3/20 | 0.69 |
| ▸ | DRD2 | P14416 | 5/20 | 0.52 |
| ▸ | HTR2A | P28223 | 3/20 | 0.52 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.50 |
| ▸ | LMNA | P02545 | 2/20 | 0.50 |
| ▸ | ALOX15 | P16050 | 2/20 | 0.50 |
| ▸ | HTT | P42858 | 1/20 | 0.48 |
| ▸ | POLB | P06746 | 1/20 | 0.45 |
| ▸ | HTR6 | P50406 | 1/20 | 0.45 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.45 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6628542 | 0.87 | HTR1A (0.72) | HTR1ASLC6A4DRD2HTR2AKDM4E | |
| SCHEMBL6628786 | 0.84 | HTR1A (0.69) | HTR1ASLC6A4DRD2HTR2AKDM4E | |
| SCHEMBL5844673 | 0.84 | HTR1A (0.69) | HTR1ASLC6A4DRD2HTR2AKDM4E | |
| SCHEMBL6767324 | 0.84 | HTR1A (0.71) | HTR1ASLC6A4DRD2HTR2AKDM4E | |
| SCHEMBL6628900 | 0.84 | HTR1A (0.78) | HTR1ASLC6A4DRD2HTR2AKDM4E | |
| SCHEMBL6627811 | 0.84 | HTR1A (0.68) | HTR1ASLC6A4DRD2HTR2AKDM4E | |
| SCHEMBL6796482 | 0.83 | HTR1A (0.75) | HTR1ASLC6A4DRD2HTR2AKDM4E | |
| SCHEMBL6628788 | 0.83 | HTR1A (0.72) | HTR1ASLC6A4DRD2HTR2AKDM4E | |
| SCHEMBL6843634 | 0.83 | HTR1A (0.72) | HTR1ASLC6A4DRD2HTR2AKDM4E | |
| SCHEMBL6333658 | 0.82 | HTR1A (0.66) | HTR1ASLC6A4DRD2HTR2AKDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1381613-B1 | ANTIDEPRESSANT AZAHETEROCYCLYLMETHYL DERIVATIVES OF OXAHETEROCYCLE-FUSED-(1,4)-BENZODIOXANS | WYETH CORP (US) | 2004-10-13 | — | — | EP | claimed |
| US-6552049-B2 | For therapy of depression, obsessive compulsive disorder, panic attacks, generalized anxiety disorder, social anxiety disorder, sexual dysfunction, eating disorders, obesity, addictive disorders caused by ethanol or cocaine abuse | WYETH | 2003-04-22 | — | — | US | claimed |
| US-20020183353-A1 | Antidepressant azaheterocyclylmethyl derivatives of oxaheterocycle-fused-[1,4]-benzodioxans | WYETH (US) | 2002-12-05 | — | — | US | claimed |
| EP-1381613-B1 | ANTIDEPRESSANT AZAHETEROCYCLYLMETHYL DERIVATIVES OF OXAHETEROCYCLE-FUSED-(1,4)-BENZODIOXANS | WYETH CORP (US) | 2004-10-13 | — | — | EP | disclosed |
| US-6706736-B2 | AMINES SUCH AS 3-(1-((8-METHYL-2,3-DIHYDROFURO(2,3-F)(1,4) BENZODIOXIN-2-YL)METHYL)-1,2,3,6-TETRAHYDRO-4-PYRIDINYL)-1H-INDOLE, ADMINISTERED AS SEROTONIN REUPTAKE INHIBITORS OR ANXIOLYTIC AGENTS | WYETH | 2004-03-16 | — | — | US | disclosed |
| EP-1389194-A2 | INHIBITORS OF BACE | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2004-02-18 | — | — | EP | disclosed |
| US-20030162805-A1 | Antidepressant azaheterocyclylmethyl derivatives of oxaheterocycle-fused-[1,4]-benzodioxans | WYETH (US) | 2003-08-28 | — | — | US | disclosed |
| US-6552049-B2 | For therapy of depression, obsessive compulsive disorder, panic attacks, generalized anxiety disorder, social anxiety disorder, sexual dysfunction, eating disorders, obesity, addictive disorders caused by ethanol or cocaine abuse | WYETH | 2003-04-22 | — | — | US | disclosed |
| US-20020183353-A1 | Antidepressant azaheterocyclylmethyl derivatives of oxaheterocycle-fused-[1,4]-benzodioxans | WYETH (US) | 2002-12-05 | — | — | US | disclosed |
| WO-2002088101-A2 | INHIBITORS OF BACE | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2002-11-07 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030162805-A1 | Antidepressant azaheterocyclylmethyl derivatives of oxaheterocycle-fused-[1,4]-benzodioxans | OPRD1, OPRM1, OPRK1 | HTR1A 27/4885SLC6A4 282/4885DRD2 10/4885 |
| US-20020183353-A1 | Antidepressant azaheterocyclylmethyl derivatives of oxaheterocycle-fused-[1,4]-benzodioxans | OPRD1, OPRM1, OPRK1 | HTR1A 27/4885SLC6A4 206/4885DRD2 17/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.